News
Apr 27, 2026
DUBLIN - The U.S. Food and Drug Administration has granted Fast Track Designation to coramitug, an investigational antibody for treating ATTR amyloidosis with…
Apr 27, 2026
Patients enrolled in more recent clinical trials for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) exhibited baseline characteristics consistent with less…
Apr 27, 2026
Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3Coramitug is being evaluated by Novo…
Apr 25, 2026
AbstractBackgroundLarge-scale, nationwide data for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Japan are limited.ObjectivesThis multicenter…
Apr 22, 2026
Webinar Session: Wednesday, April 22nd at 6 PM (ET) Zoom Meeting(These sessions will not be recorded due to patient involvement and HIPAA laws)To Register …
Apr 21, 2026
AbstractBackground and AimsEarly detection is important given the availability of new disease-modifying therapies and the high prevalence of transthyretin amyloid…
Apr 21, 2026
CNIC scientists identify a biomarker that improves risk prediction in a severe form of heart failure
The biomarker MR-proADM improves risk prediction in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and is associated with greater disease…
Apr 21, 2026
Clearing established amyloid deposits from the heart — not merely slowing their formation — is the defining unmet need in ATTR cardiac amyloidosis. This report maps…
Apr 21, 2026
AbstractTransthyretin amyloidosis (ATTR) is a rapidly evolving disease with a rising prevalence and improving prognosis. With an increasing number of patients…
Apr 20, 2026
Carpal tunnel syndrome (CTS) in both wrists may be a red flag of transthyretin amyloidosis (ATTR), including hereditary transthyretin amyloidosis with…